Search Results
Your search for what matches 6129 pages
Showing 1 - 50Four-Year Outcomes Highlight Efficacy of Neoadjuvant Nivolumab and Relatlimab in Advanced Resectable Melanoma
A neoadjuvant and adjuvant regimen of anti–PD-1 therapy with nivolumab and anti–LAG-3 therapy with relatlimab led to a 4-year event-free survival rate of 80% in patients with advanced, resectable melanoma, according to long-term findings from a phase II study published in the Journal of Clinical...
A Young Hematologist’s Take on ICML 2025
From Dr. Bruce Cheson’s electric speech on how it all started with pentostatin in hairy cell leukemia, to the introduction of bendamustine in indolent lymphoma, to the development of R-squared (an innovative chemotherapy-free approach to treating lymphoma)—the nostalgia at the International...
AJCC Guideline Reassessment Aims to Improve HPV-Positive Throat Cancer Staging
An update of staging guidelines from the American Joint Committee on Cancer (AJCC) for human papillomavirus (HPV)-positive throat cancer—now more common in the United States than cervical cancer, according to the American Cancer Society—aims to make treatment of early-stage disease more consistent...
The Future of Cell Therapy: Optimizing the CAR to the Disease in B-Cell Malignancies
Over the past 20 years, increased understanding of the biological mechanism of disease has led to improved treatment options for all malignancies. Within each disease subtype, we have molecularly characterized tumors and developed specific treatment algorithms to optimize patient outcomes. Among...
Can Planned C-Sections Increase the Risk of Childhood ALL?
Children born by planned cesarean section (C-section) may have an increased risk of developing acute lymphoblastic leukemia (ALL) later in life, according to a recent study published by Kampitsi et al in the International Journal of Cancer. Alhough the researchers did find an association, they...
Survey Finds Confusion Over Mammogram Guidelines
Mammograms can detect breast cancer early before symptoms appear, and regular screening decreases the risk of dying from breast cancer. But a recent survey conducted by the Annenberg Public Policy Center (APPC) of the University of Pennsylvania shows that some Americans appear to be confused about...
Study Finds AI Chatbots Are Vulnerable to Spreading Malicious, False Health Information
While artificial intelligence (AI) large language models (LLMs) hold the promise to help consumers find trustworthy health information, a study assessing the safeguards incorporated into these models has found that they are vulnerable to malicious instruction that converts them into health...
I Was Expecting to Hear I Have Heart Disease, Not Cancer
In 2022, I had a computed tomography (CT) coronary calcium scan to see whether there were any signs of narrowing or blockage in my heart arteries. Heart disease runs in my family. My father died of a heart attack the year before, and I worried that I was at risk for the same fate. It was a complete ...
W. Kimryn Rathmell, MD, PhD, FASCO, Selected for Women Who Conquer Cancer Mentorship Award
W. Kimryn Rathmell, MD, PhD, FASCO, has been selected for the prestigious 2025 Hologic, Inc Endowed Women Who Conquer Cancer Mentorship Award. Launched in 2016, the Women Who Conquer Cancer award program honors extraordinary women leaders in oncology and role models who have excelled as mentors...
Malignant Hematology Expert and Medicare Reimbursement Advocate, Samuel M. Silver, MD, PhD, FRCP, FASCO, MACP, Dies at 74
The ASCO Post would like to pay tribute to Samuel M. Silver, MD,PhD, FRCP, FASCO, MACP, who died on August 14, 2024, at the age of 74. Dr. Silver was renowned in the hematology and oncology community and a respected member of the editorial advisory board of The ASCO Post. Additionally, he served...
Minnesota Society of Clinical Oncology Recognized for Advocacy at 2025 ASCO Annual Meeting
The Minnesota Society of Clinical Oncology (MSCO) is the recipient of the 2024 Jeffery C. Ward Affiliate Advocacy Award. The Association for Clinical Oncology presented the award during the State Affiliates’ Reception at the 2025 ASCO Annual Meeting. Presented annually, the Jeffery C. Ward...
HLA-Matching Considerations for Hematopoietic Cell Transplantation in Hematologic Malignancies
Besides relapse of the malignant disease, graft-vs-host disease is still one of the greatest concerns, in terms of adverse effects, following a hematopoietic cell transplantation (HCT) in a patient with a hematologic malignancy. To mitigate these concerns, investigators are continually analyzing ...
ASCO Guideline Update Calls for Omission of SLNB in Select Patients With Early-Stage Breast Cancer
ASCO has released a clinical practice guideline update on the role of sentinel lymph node biopsy (SLNB) in early-stage breast cancer.1 The update includes recommendations based on findings from trials released after the published guideline in 2017, including data from nine randomized trials...
Adjuvant Use of Atezolizumab Plus Chemotherapy in DNA Mismatch Repair–Deficient Colon Cancer
For the adjuvant treatment of stage III colon cancer with DNA mismatch repair–deficient (dMMR) tumors, the addition of the checkpoint inhibitor atezolizumab to standard chemotherapy significantly improved disease-free survival in the phase III ATOMIC trial. The results position this approach as a...
Cohort Study Finds Genetics of Cardiomyopathy Risk in Cancer Survivors Differ by Age of Onset
The relationship between genetic variants and the risk of late-onset cardiomyopathy remains poorly understood in survivors of childhood cancer despite being otherwise well established. Scientists from St. Jude Children’s Research Hospital have helped address this gap, assessing whether variant...
ASH 2025 Awardees: Hematologists to Be Honored With Highest Distinctions
The American Society of Hematology (ASH) announced that it will recognize 11 hematologists who have made notable contributions to the field with several honorific awards and prestigious lectures at the 2025 ASH Annual Meeting & Exposition in Orlando, Florida, from December 6–9, 2025. The...
How a Commonly Inherited Genetic Alteration Is Driving Breast Cancer Metastasis and Predicting Survival
A common germline variant in the proprotein convertase subtilisin/kexin type 9 (PCSK9) (rs562556, V474I) gene rather than a mutation in a breast cancer tumor may be the driving force in significantly increasing the risk of breast cancer metastasis and reducing survival in women with the disease....
Establishing Novel Models of Interdisciplinary Care to Improve Survival Outcomes in Patients With Cancer
Internationally renowned for her decades-long pioneering research in pancreatic cancer, in 2024, Diane M. Simeone, MD, left her positions as the Laura and Isaac Perlmutter Professor of Surgery and Pathology; Director, Pancreatic Cancer Center; and Associate Director of the Perlmutter Cancer Center...
How I Discuss the Current Political Chaos When Patients Ask Health-Related Questions About It
I’ve been a physician for several decades, seeing patients and functioning as a medical teacher; clinical, translational, and bench researcher; and administrator. Adapting to medical practice in three nations and several U.S. states has been quite challenging at different times, but I really think...
Novel Tri-Specific Antibody Shows Efficacy and Safety in Refractory Myeloma
According to the initial findings of an ongoing first-in-human phase I trial, reported at the European Hematology Association (EHA) 2025 Congress, promising results have been shown for a novel off-the-shelf tri-specific antibody in the treatment of patients with multiple myeloma highly refractory...
Chronicling the Extraordinary Career of Stephen R. Grobmyer, MD, FACS, in Breast Cancer Research, Surgery, and Treatment
In this installment of The ASCO Post’s Living a Full Life series, Guest Editor Jame Abraham, MD, FACP, spoke with Stephen R. Grobmyer, MD, FACS, about his clinical and research career in oncology, the challenges and rewards of moving to Abu Dhabi and building a state-of-the-art cancer center, and...
BRCA Mutations Could Increase Risk of Rare Lymphoma Among Women Who Received Textured Breast Implants During Breast Cancer Treatment
The risk of developing breast implant–associated anaplastic large-cell lymphoma (ALCL) could be higher among women with breast cancer and BRCA1 or BRCA2 mutations who received textured breast implants as part of their postmastectomy reconstructive surgery compared with patients lacking the genetic...
Low-Value Cancer Screenings May Continue for Years Following Guideline Change to Limit Unnecessary Tests
Stopping the widespread use of unnecessary, potentially harmful cancer screenings may take up to 13 years and potentially longer following the implementation of new guidelines, according to a recent study published by LeLaurin et al in BMJ Quality & Safety. Background The U.S. Preventive...
I Was an N-of-1 in a CAR T-Cell Therapy Trial for Ovarian Cancer
More than a decade after I was diagnosed with late-stage ovarian cancer, a phase I clinical trial at Moffitt Cancer Center and Research Institute in Tampa, Florida, investigating a dose of a novel follicle-stimulating hormone receptor (FSHR)-targeting chimeric antigen receptor (CAR) T-cell therapy...
Why Black Women Have a Higher Risk of Dying of All Types of Breast Cancer Than White Women
The disparities in breast cancer incidence and mortality rates between Black and White women in the United States have been well documented. Studies over the past decade consistently show that although Black women have a 4% lower breast cancer incidence rate than White women, they are still between ...
ASTRO Survey Data Illustrate Impact of Continued Medicare Cuts on Cancer Care
Recent national survey data from the American Society for Radiation Oncology (ASTRO) have shown that further cuts to Medicare reimbursement for radiation therapy would increase patient wait times for cancer treatment and force clinic downsizing. Nearly all (96%) of the 675 physicians responding to...
How the Elimination of Federal Gender-Related Grants and DEI Programs Is Impacting LGBTQ+ Health Research
Within hours of the start of his second administration, on January 20, 2025, President Donald Trump signed an executive order proclaiming that the country would now recognize only two sexes, male and female, essentially rejecting transgender identity, and directing all federal agencies to use the...
Improving the Alliance Between Oncologists and Primary Care Providers: A Call for Collaborative Action
Experts and patients alike would agree that navigating the current fragmented U.S. health-care system is not an easy task. One component of that disconnection may center on the relationship between oncology and primary care. The benefits of collaboration between oncologists and primary care...
Overall Survival Benefit Achieved With Inavolisib Plus Palbociclib and Fulvestrant in Advanced Breast Cancer
“Inavolisib plus palbociclib and fulvestrant significantly improved overall survival compared with placebo plus palbociclib/fulvestrant…. This is the first time overall survival has been significantly improved by a PI3K pathway–targeted drug,” said Nicholas Turner, MD, PhD, FRCP,FMedSci, who...
Hope S. Rugo, MD, FASCO, and Rebecca Alexandra Dent, MD, FASCO, on Breast Cancer Data Highlights: Sequencing of Endocrine Therapy
Hope S. Rugo, MD, FASCO, of City of Hope, and Rebecca Alexandra Dent, MD, FASCO, of National Cancer Centre Singapore, review the results of a biomarker analysis of the DESTINY-Breast06 trial, which evaluated trastuzumab deruxtecan after endocrine therapy in patients with metastatic breast cancer...
Treatment for Intractable Cancer Pain Pioneered
A novel therapy based on the plant-derived molecule resiniferatoxin could be a safe and effective agent for patients with difficult-to-control cancer pain, according to a recent study published by Mannes et al in NEJM Evidence. Background Resiniferatoxin is derived from Euphorbia resinifera, a...
Early Driver of Lineage Plasticity in Prostate Cancer Cells
Researchers have identified a gene that could play a key role in the transition to a more aggressive, treatment-resistant type of prostate cancer, according to a recent study published by Duan et al in the Journal of Clinical Investigation. The findings indicated that the gene may be indirectly...
Anti-Inflammatory Diet Could Benefit Survival Following Stage III Colorectal Cancer
Consuming an anti-inflammatory diet could improve posttreatment survival among patients with colorectal cancer compared with following a proinflammatory diet, according to new findings presented by Char et al at the 2025 ASCO Annual Meeting (Abstract LBA3509). The findings suggested that engaging...
Scholastic Performance Among Adolescents and Young Adults With Cancer
Adolescent and young adult (AYA) patients with cancer may need support for scholastic performance, according to new findings presented by Fisher et al at the 2025 ASCO Annual Meeting (Abstract 11053). Previous studies have shown how a cancer diagnosis could disrupt the typical developmental...
Menopause Medication May Help to Prevent Invasive Breast Cancer, Study Finds
A drug already approved by the FDA to treat menopause symptoms may also help to prevent invasive breast cancer, according to recent findings from a clinical trial led by Northwestern Medicine. The research was presented at the 2025 ASCO Annual Meeting (Abstract 512). Study Details The multicenter,...
ASCO 2025: Structured Exercise Program Improves Survival, Outcomes in Some Patients With Colon Cancer
A phase III study has found that a 3-year structured exercise program initiated soon after completion of adjuvant chemotherapy improves disease-free and overall survival, as well as patient-reported physical functioning and health-related fitness, in patients with stage III and high-risk stage II...
How Family Adventures, Precision Oncology, and Living Purposefully Bring Balance to the Life of Charu Aggarwal, MD, MPH, FASCO
At just 5 years old, Charu Aggarwal, MD, MPH, FASCO, already knew that she wanted to be a physician when she grew up, although she can’t explain where the idea came from. She just knows the desire to help others was ingrained in her from a very early age. Growing up in New Delhi, India, where...
Mark Cuban Does It Again: Reshuffling the Deck of Front-Line CML Therapy
With the currently available BCR::ABL1 tyrosine kinase inhibitors, chronic myeloid leukemia (CML) has transformed from an invariably fatal disorder (10-year overall survival < 10%) to an indolent one, associated with a near-normal life expectancy on optimal tyrosine kinase inhibitor...
DOJ Finds Federal Bureau of Prisons’ Colorectal Cancer Screening Practices Lacking
An evaluation by the Department of Justice Office of the Inspector General (DOJ OIG) of the Federal Bureau of Prisons’ (BOP) colorectal cancer screening practices for inmates and their clinical follow-up for positive screenings found several serious operational and managerial deficiencies...
I Have Stage IV Lung Cancer and Still Consider Myself the Luckiest Man in the World
Although I have spent the past 2 decades of my medical career as a primary care physician, educator, and researcher in conditions that disproportionately affect people of Asian descent, including lung cancer, I was still unprepared to hear the words “You have stage IV non–small cell lung...
Bringing Evidence-Based Integrative Medicine Into Everyday Oncology Practice
Despite the significant rise over the past 50 years in the use of evidence-based integrative medicine in conjunction with conventional cancer treatments—up from just 20% in the 1970s to about 80% in 20171—training opportunities in the fundamentals of this emerging field within the specialty of...
What Is the Value in Cost and Lives Saved of Cancer Screening and Prevention?
Several recent studies have shown the value of cancer screening in reducing the number of deaths from the disease. One study using computer modeling to estimate the number of cancer-related deaths that could be averted by increasing the use of U.S. Preventive Services Task Force (USPSTF)...
Together, We’re Building a Better Future for People With Cancer and for Our Profession
For more than 25 years, my goal as a community oncologist has been to ensure that all patients have access to the highest-quality cancer care. This is the future I stood for when I became ASCO’s 61st President and what I know our more than 50,000 members stand for. And I believe we will get there...
The Power of Translational Science to Transform the Lives of Patients Worldwide
Despite a 30-year history as an ASCO volunteer, for Eric J. Small, MD, FASCO, this past year as President-Elect has opened new perspectives on the organization he will soon lead as ASCO’s 62nd President, effective during the 2025 ASCO Annual Meeting, May 30–June 3, 2025, in Chicago. After serving...
WGS Liquid Biopsies for HPV-Associated Head and Neck Squamous Cell Carcinoma
Whole-genome sequencing (WGS)-based circulating tumor DNA (ctDNA) detection of human papillomavirus (HPV)-associated head and neck squamous cell carcinoma (HNSCC), termed HPV-DeepSeek by the study investigators, showed greater sensitivity, specificity, and diagnostic accuracy than any current...
Cellular Therapies Show Sustained Promise in Hematologic Malignancies, but Access Remains Uneven
Cellular therapies such as chimeric antigen receptor (CAR) T-cell therapy and tumor-infiltrating lymphocyte therapy are transforming outcomes for patients with cancer, particularly in the relapsed or refractory setting. “We’re seeing outstanding response rates in patients with B-cell malignancies...
Case 3: Refractory AML with Complex Karyotype and TP53 Mutation
This is Part 3 of Navigating the Complexities of Relapsed/Refractory AML: Identifying Mutations and Optimizing Targeted Therapy, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Uma Borate, Naval Daver, and Joshua Zeidner...
FDA OCE Announces Project Interface Outreach Initiative
The Oncology Center of Excellence (OCE) at the U.S. Food and Drug Administration (FDA) has launched Project Interface to advance engagement and outreach to patients with cancer, advocacy organizations, and oncology experts. Its mission is to protect, promote, and advance public health by...
Collaborative Strategy Involving AI, Human Task-Sharing Could Help Minimize Mammogram Costs
When screening for breast cancer, the most effective strategy to utilize artificial intelligence (AI) may involve collaboration with human radiologists, according to a recent study published by Ahsen et al in Nature Communications. The findings could help shape how hospitals and clinics integrate...
How Could So Many Physicians Have Failed Me?
The first sign that something was terribly wrong was in 2015, when I began to feel so fatigued that it was difficult to get out of bed even after 8 to 10 hours of sleep. I’ve been full of energy my whole life and couldn’t understand why I was so tired all the time. Then I began to experience...
